ZA200703069B - Quinoxalines as B Raf inhibitors - Google Patents

Quinoxalines as B Raf inhibitors

Info

Publication number
ZA200703069B
ZA200703069B ZA200703069A ZA200703069A ZA200703069B ZA 200703069 B ZA200703069 B ZA 200703069B ZA 200703069 A ZA200703069 A ZA 200703069A ZA 200703069 A ZA200703069 A ZA 200703069A ZA 200703069 B ZA200703069 B ZA 200703069B
Authority
ZA
South Africa
Prior art keywords
quinoxalines
raf inhibitors
raf
inhibitors
Prior art date
Application number
ZA200703069A
Other languages
English (en)
Inventor
Aquila Brian
Deegan Tracey
Lee Stephen
Pontz Timothy
Dakin Les
Loannidis Stephanos
Lyne Paul
Su Mei
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of ZA200703069B publication Critical patent/ZA200703069B/xx

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D241/00Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/36Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings condensed with carbocyclic rings or ring systems
    • C07D241/38Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings condensed with carbocyclic rings or ring systems with only hydrogen or carbon atoms directly attached to the ring nitrogen atoms
    • C07D241/40Benzopyrazines
    • C07D241/44Benzopyrazines with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the hetero ring
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D409/00Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/498Pyrazines or piperazines ortho- and peri-condensed with carbocyclic ring systems, e.g. quinoxaline, phenazine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D241/00Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/36Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings condensed with carbocyclic rings or ring systems
    • C07D241/38Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings condensed with carbocyclic rings or ring systems with only hydrogen or carbon atoms directly attached to the ring nitrogen atoms
    • C07D241/40Benzopyrazines
    • C07D241/42Benzopyrazines with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to carbon atoms of the hetero ring
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D409/00Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
ZA200703069A 2004-10-15 2007-04-13 Quinoxalines as B Raf inhibitors ZA200703069B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US61937304P 2004-10-15 2004-10-15

Publications (1)

Publication Number Publication Date
ZA200703069B true ZA200703069B (en) 2008-08-27

Family

ID=35840309

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA200703069A ZA200703069B (en) 2004-10-15 2007-04-13 Quinoxalines as B Raf inhibitors

Country Status (13)

Country Link
US (1) US20080207616A1 (fr)
EP (1) EP1828147A1 (fr)
JP (1) JP2008516939A (fr)
KR (1) KR20070063044A (fr)
CN (1) CN101080396A (fr)
AU (1) AU2005293384A1 (fr)
BR (1) BRPI0518126A (fr)
CA (1) CA2583096A1 (fr)
IL (1) IL182359A0 (fr)
MX (1) MX2007004480A (fr)
NO (1) NO20071776L (fr)
WO (1) WO2006040568A1 (fr)
ZA (1) ZA200703069B (fr)

Families Citing this family (67)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HU0500126D0 (en) * 2005-01-26 2005-04-28 Sanofi Aventis New compounds and process for their preparation
US7754717B2 (en) 2005-08-15 2010-07-13 Amgen Inc. Bis-aryl amide compounds and methods of use
US8119655B2 (en) 2005-10-07 2012-02-21 Takeda Pharmaceutical Company Limited Kinase inhibitors
DK1957461T3 (en) * 2005-11-14 2016-12-19 Genentech Inc Bisamidhæmmere the hedgehog-signalling
JP2009532450A (ja) * 2006-04-05 2009-09-10 アストラゼネカ アクチボラグ 化合物
MX2009003793A (es) 2006-10-09 2009-12-14 Takeda Pharmaceutical Inhibidores de cinasa.
CL2008000986A1 (es) 2007-04-06 2008-10-17 Neurocrine Biosciences Inc COMPUESTO DERIVADO DE HETEROCICLOS DE NITROGENO, AGONISTAS DEL RECEPTOR GnRH; COMPOSICION FARMACEUTICA QUE COMPRENDE A DICHO COMPUESTO; Y USO PARA TRATAR UNA AFECCION RELACIONADA CON LAS HORMONAS SEXUALES, ENDOMETRIOSIS, DISMENORREA, ENFERMEDAD DE OV
NZ580457A (en) 2007-04-06 2012-03-30 Neurocrine Biosciences Inc Gonadotropin-releasing hormone receptor antagonists and methods relating thereto
AR067354A1 (es) 2007-06-29 2009-10-07 Sunesis Pharmaceuticals Inc Compuestos utiles como inhibidores de la raf quinasa
DK2229391T3 (da) 2007-12-19 2014-10-13 Cancer Res Inst Royal Pyrido[2,3-B]pyrazin-8-substituerede forbindelser og deres anvendelse
JP2011513332A (ja) * 2008-02-29 2011-04-28 アレイ バイオファーマ、インコーポレイテッド 癌の治療のためのraf阻害剤としてのn−(6−アミノピリジン−3−イル)−3−(スルホンアミド)ベンズアミド誘導体
KR20100122505A (ko) * 2008-02-29 2010-11-22 어레이 바이오파마 인크. Raf 저해물질 화합물 및 이들의 이용 방법
WO2009111277A1 (fr) * 2008-02-29 2009-09-11 Array Biopharma Inc. Dérivés d'imidazo[4,5-b]pyridine utilisés comme inhibiteurs de raf
TW200940539A (en) * 2008-02-29 2009-10-01 Array Biopharma Inc RAF inhibitor compounds and methods of use thereof
CN102480966B (zh) 2009-06-12 2015-09-16 达娜-法勃肿瘤研究所公司 融合的杂环化合物及其用途
GB0913342D0 (en) 2009-07-31 2009-09-16 Astrazeneca Ab Compounds - 801
EP2519517B1 (fr) 2009-12-29 2015-03-25 Dana-Farber Cancer Institute, Inc. Inhibiteurs de kinase raf de type ii
PL2531502T3 (pl) 2010-02-01 2014-08-29 Cancer Research Tech Ltd 1-(5-tert-Butylo-2-fenylo-2H-pirazol-3-ilo)-3-[2-fluoro-4-(1-metylo-2-okso-2,3-dihydro-1H-imidazo[4,5-b]pirydyn-7-yloksy)-fenylo]-mocznik i związki pokrewne oraz ich zastosowanie w terapii
GB201007286D0 (en) 2010-04-30 2010-06-16 Astex Therapeutics Ltd New compounds
WO2011147764A1 (fr) 2010-05-28 2011-12-01 N.V. Organon Composés thiéno(2,3b)pyrazine en tant qu'inhibiteurs de b-raf
CN107245056A (zh) 2011-08-26 2017-10-13 润新生物公司 化学实体、组合物及方法
CN115403531A (zh) * 2011-09-14 2022-11-29 润新生物公司 作为激酶抑制剂的化学实体、组合物及方法
EP2757885B1 (fr) * 2011-09-21 2017-03-15 Neupharma, Inc. Entités chimiques, compositions, et procédés spécifiques
WO2013049701A1 (fr) * 2011-09-30 2013-04-04 Neupharma, Inc. Certaines entités chimiques, compositions et procédés
GB201118654D0 (en) * 2011-10-28 2011-12-07 Astex Therapeutics Ltd New compounds
US9382239B2 (en) 2011-11-17 2016-07-05 Dana-Farber Cancer Institute, Inc. Inhibitors of c-Jun-N-terminal kinase (JNK)
AU2012356374B2 (en) 2011-12-21 2017-06-22 Ono Pharmaceutical Co., Ltd. Pyridinone and pyrimidinone derivatives as factor XIa inhibitors
WO2013109142A1 (fr) 2012-01-16 2013-07-25 Stichting Het Nederlands Kanker Instituut Inhibition de la voie des mapk/erk et pdk combinée dans des cas de néoplasie
EP2806874B1 (fr) 2012-01-25 2017-11-15 Neupharma, Inc. Dérivés de quinoxaline-oxy-phenyl comme inhibiteurs de kinases
CN102608316B (zh) * 2012-02-22 2014-05-07 北京维德维康生物技术有限公司 检测喹噁啉类化合物的试剂盒或试纸条
CN106977495B (zh) 2012-04-24 2020-08-04 沃泰克斯药物股份有限公司 Dna-pk抑制剂
US9688635B2 (en) 2012-09-24 2017-06-27 Neupharma, Inc. Certain chemical entities, compositions, and methods
EP2909194A1 (fr) 2012-10-18 2015-08-26 Dana-Farber Cancer Institute, Inc. Inhibiteurs de cycline-dépendante kinase 7 (cdk7)
US9758522B2 (en) 2012-10-19 2017-09-12 Dana-Farber Cancer Institute, Inc. Hydrophobically tagged small molecules as inducers of protein degradation
US10000483B2 (en) 2012-10-19 2018-06-19 Dana-Farber Cancer Institute, Inc. Bone marrow on X chromosome kinase (BMX) inhibitors and uses thereof
EP2916838B1 (fr) * 2012-11-12 2019-03-13 Neupharma, Inc. Certaines entités chimiques, compositions et certains procédés
WO2014121885A1 (fr) 2013-02-07 2014-08-14 Merck Patent Gmbh Dérivés de quinoxaline substitués et leur utilisation à titre de modulateurs allostériques positifs du mglur4
ES2900061T3 (es) 2013-03-12 2022-03-15 Vertex Pharma Inhibidores de DNA-PK
US9629851B2 (en) 2013-09-20 2017-04-25 Stitching Het Nederlands Kanker Institut—Antoni Van Leeuwenhoek Ziekenhuis ROCK in combination with MAPK pathway
WO2015041534A1 (fr) 2013-09-20 2015-03-26 Stichting Het Nederlands Kanker Instituut P90rsk en combinaison avec raf/erk/mek
GB201317609D0 (en) 2013-10-04 2013-11-20 Cancer Rec Tech Ltd Inhibitor compounds
EP3424920B1 (fr) 2013-10-17 2020-04-15 Vertex Pharmaceuticals Incorporated Co-cristaux de (s)-n-méthyl-8-(1-((2 '-méthyl-[4,5'-bipyrimidin] -6-yl)amino) propan-2-yl)quinoline-4-carboxamide et leurs dérivés deutérés en tant qu'inhibiteurs de l'adn-pk
EP3057956B1 (fr) 2013-10-18 2021-05-05 Dana-Farber Cancer Institute, Inc. Inhibiteurs polycycliques de la kinase cycline-dépendante 7 (cdk7)
AU2014337122B2 (en) 2013-10-18 2019-01-03 Dana-Farber Cancer Institute, Inc. Heteroaromatic compounds useful for the treatment of proliferative diseases
GB201320732D0 (en) 2013-11-25 2014-01-08 Cancer Rec Tech Ltd Methods of chemical synthesis
GB201320729D0 (en) 2013-11-25 2014-01-08 Cancer Rec Tech Ltd Therapeutic compounds and their use
WO2015144808A1 (fr) 2014-03-26 2015-10-01 Astex Therapeutics Ltd Combinaisons d'un inhibiteur de fgfr et d'un inhibiteur d'igf1r
SI3122358T1 (sl) 2014-03-26 2021-04-30 Astex Therapeutics Ltd. Kombinacije FGFR- in CMET-inhibitorjev za zdravljenje raka
JO3512B1 (ar) 2014-03-26 2020-07-05 Astex Therapeutics Ltd مشتقات كينوكسالين مفيدة كمعدلات لإنزيم fgfr كيناز
US10017477B2 (en) 2014-04-23 2018-07-10 Dana-Farber Cancer Institute, Inc. Janus kinase inhibitors and uses thereof
US9862688B2 (en) 2014-04-23 2018-01-09 Dana-Farber Cancer Institute, Inc. Hydrophobically tagged janus kinase inhibitors and uses thereof
EP3169670B1 (fr) * 2014-07-16 2021-10-20 Development Center for Biotechnology Dérivés sulfonamides de n-(3-(quinoxalin-6-ylamino)phényl)alkane en tant qu'inhibiteurs de la kinase b-raf pour le traitement du cancer
CA2972239A1 (fr) 2014-12-23 2016-06-30 Dana-Farber Cancer Institute, Inc. Inhibiteurs de la kinase cycline-dependante 7 (cdk7)
JOP20200201A1 (ar) 2015-02-10 2017-06-16 Astex Therapeutics Ltd تركيبات صيدلانية تشتمل على n-(3.5- ثنائي ميثوكسي فينيل)-n'-(1-ميثيل إيثيل)-n-[3-(ميثيل-1h-بيرازول-4-يل) كينوكسالين-6-يل]إيثان-1.2-ثنائي الأمين
JP6861166B2 (ja) 2015-03-27 2021-04-21 ダナ−ファーバー キャンサー インスティテュート, インコーポレイテッド サイクリン依存性キナーゼの阻害剤
GB201505658D0 (en) 2015-04-01 2015-05-13 Cancer Rec Tech Ltd Inhibitor compounds
CN104876879B (zh) * 2015-04-14 2018-05-18 中国科学院合肥物质科学研究院 一种bcr-abl激酶抑制剂
AU2016276963C1 (en) 2015-06-12 2021-08-05 Dana-Farber Cancer Institute, Inc. Combination therapy of transcription inhibitors and kinase inhibitors
WO2017044858A2 (fr) 2015-09-09 2017-03-16 Dana-Farber Cancer Institute, Inc. Inhibiteurs de kinases cycline-dépendantes
BR112018005637B1 (pt) 2015-09-23 2023-11-28 Janssen Pharmaceutica Nv Compostos derivados de quinoxalina, quinolina e quinazolinona,composições farmacêuticas que os compreende, e uso dos referidos compostos
ES2904513T3 (es) 2015-09-23 2022-04-05 Janssen Pharmaceutica Nv 1,4-Benzodiazepinas biheteroarilo sustituidas y usos de las mismas para el tratamiento del cáncer
US11110108B2 (en) 2016-09-27 2021-09-07 Vertex Pharmaceuticals Incorporated Method for treating cancer using a combination of DNA-damaging agents and DNA-PK inhibitors
GB201617103D0 (en) 2016-10-07 2016-11-23 Cancer Research Technology Limited Compound
GB201807845D0 (en) 2018-05-15 2018-06-27 Univ Manchester Kinase Inhibitors
BR112021018168B1 (pt) 2019-03-21 2023-11-28 Onxeo Composição farmacêutica, combinação e kit compreendendo uma molécula dbait e um inibidor de quinase para o tratamento de câncer
KR20220098759A (ko) 2019-11-08 2022-07-12 인쎄름 (엥스띠뛰 나씨오날 드 라 쌍떼 에 드 라 흐쉐르슈 메디깔) 키나제 억제제에 대해 내성을 획득한 암의 치료 방법
WO2021148581A1 (fr) 2020-01-22 2021-07-29 Onxeo Nouvelle molécule dbait et son utilisation

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
OA11746A (en) * 1999-01-13 2005-05-13 Warner Lambert Co Benzoheterocycles and their use as MEK inhibitors.
CA2480638C (fr) * 2002-03-29 2013-02-12 Chiron Corporation Benzazoles substitues et leur utilisation en tant qu'inhibiteurs de la kinase raf

Also Published As

Publication number Publication date
MX2007004480A (es) 2007-05-08
IL182359A0 (en) 2007-07-24
CN101080396A (zh) 2007-11-28
KR20070063044A (ko) 2007-06-18
EP1828147A1 (fr) 2007-09-05
WO2006040568A1 (fr) 2006-04-20
NO20071776L (no) 2007-04-25
JP2008516939A (ja) 2008-05-22
BRPI0518126A (pt) 2008-10-28
CA2583096A1 (fr) 2006-04-20
US20080207616A1 (en) 2008-08-28
AU2005293384A1 (en) 2006-04-20

Similar Documents

Publication Publication Date Title
ZA200703069B (en) Quinoxalines as B Raf inhibitors
IL185024A0 (en) Raf inhibitor compounds and methods
IL179398A0 (en) Dpp-ib inhibitors
ZA200707650B (en) Azolylacylguanidines as ß-secretase inhibitors
ZA200606683B (en) Pyrazolotriazines as kinase inhibitors
ZA200608221B (en) Thiadlazolidinones as GSK-3 Inhibitors
AP2006003810A0 (en) 4-Phenylamino-quinazolin-6-yl-amides
DE602005007474D1 (en) Substituierte morpholin- und thiomorpholinderivate
DE502005007040D1 (en) Laryngoskop
DE602004014986D1 (en) Terminal-box
DE502005007456D1 (en) Nanoemulsionen
DE602005008719D1 (en) Notinformationsschild
DE602005010119D1 (en) Roboterhandvorrichtung
DE502005009795D1 (en) Modulares gelenkprothesensystem
DE602005003029D1 (en) Polyaminoamidmonoepoxyaddukte
DE502004004685D1 (en) Giessmaschine
DE502005010653D1 (en) Eiten
GB0421355D0 (en) Inhibitors
DE502005006813D1 (en) Common-rail-injektor
GB0421356D0 (en) Inhibitors
DE502004004917D1 (en) Multiaxialkomplex
GB0516967D0 (en) Inhibitors
GB0418238D0 (en) Up yours- Barb-B-Q
AU304810S (en) Parer
DE502005004945D1 (en) Auto-splice-system